Related Experiment Videos
Summary
Serious Candida infections in surgical patients were linked to underlying conditions and treatments like broad-spectrum antibiotics and TPN. Adequate amphotericin B dosage proved crucial for survival, with no deaths in patients receiving over 200 mg.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Surgical Infections
Background:
- Serious Candida infections present a significant risk in surgical patients.
- Elderly patients and those with underlying health issues are particularly vulnerable.
- Broad-spectrum antibiotics and total parenteral nutrition (TPN) are identified as potential predisposing factors.
Purpose of the Study:
- To analyze the incidence and outcomes of serious Candida infections in surgical patients.
- To identify risk factors associated with Candida infections in this population.
- To evaluate the efficacy of amphotericin B in treating invasive Candida infections.
Main Methods:
- Retrospective analysis of 55 surgical patients diagnosed with serious Candida infections between January 1977 and December 1980.
- Review of patient records for underlying conditions, treatments, and microbiological cultures (blood, bile).
- Assessment of treatment outcomes, focusing on mortality rates and the impact of amphotericin B dosage.
Main Results:
- A 38% mortality rate was observed in patients with serious Candida infections.
- Positive blood or bile cultures for Candida were associated with a high fatality rate.
- Intravenous amphotericin B demonstrated high efficacy; no deaths occurred with doses exceeding 200 mg, compared to 56% mortality with lower doses.
Conclusions:
- Candida infections pose a severe threat in surgical settings, especially for elderly and immunocompromised individuals.
- TPN and broad-spectrum antibiotics may increase the risk of invasive candidiasis.
- Adequate dosing of intravenous amphotericin B is critical for successful treatment and improved survival rates in patients with serious Candida infections.